Perceiv AI Company Research Report

Company Overview

• Name: Perceiv AI

• Mission: Perceiv AI is dedicated to pioneering disease forecasting to transform clinical trials and redefine patient care by leveraging advanced artificial intelligence and machine learning techniques.

• Founded: No information is available

• Founders:

• Christian Dansereau, Ph.D. (CEO & Founder)

• César Laurent, Ph.D. (CTO & Founder)

• Key People:

• Christian Dansereau, Ph.D. (CEO & Founder)

• César Laurent, Ph.D. (CTO & Founder)

• Angela Tam, Ph.D. (Senior Scientist)

• Adrián Noriega de la Colina, M.D., Ph.D. (Clinical and Regulatory Lead)

• Maxime Jacques, M.A.Sc (Software Engineer)

• Christine Newton, C.P.A. (VP Finance)

• Simona Skerjanec, MBA (Board of Directors)

• Richard H. Stark, M.S. (Board of Directors)

• Advisors: Yoshua Bengio, Ph.D.; Serge Gauthier, M.D.; Betsabeh Madani Hermann, M.B.A.

• Headquarters: 7.117-1700 Saint-Patrick St, Montreal, Canada, H3K 1A7

• Number of Employees: No information is available

• Revenue: No information is available

• Industry Recognition: Known for developing a multimodal prognostic platform to forecast disease progression in age-related disorders, particularly in Alzheimer's disease, leveraging the AD-Px™ prognostic engine.

Products

• Foresight™️ Predictive Platform:

• Multimodal Capabilities: The platform leverages multiple sources of data including imaging, genetic, phenotypic, molecular, and clinical variables to better characterize individuals.

• High Precision Targeting: Ability to precisely target subgroups in large, heterogeneous populations rapidly.

• Highly Actionable Insights: Digital biomarkers are highly specific and validated, ready for action in any clinical setting.

• AD-Px™ Engine: A specialized tool within the platform designed for Alzheimer's disease, assisting in accelerating trials by reducing screen failure rates.

Recent Developments

Company Announcements:

• Board Changes:

• Simona Skerjanec joined the Board of Directors on October 14, 2024.

• Certifications & Achievements:

• ISO 27001 Certification obtained on May 7, 2024, demonstrating commitment to data security and privacy.

• Achieved HIPAA Compliance on November 28, 2023.

• Collaborations & Partnerships:

• Partnered with Alleo Labs on January 8, 2024, to optimize clinical trials using AI and prognostic biomarkers.

• Joined Johnson & Johnson's JLABS Global Network on June 21, 2023.

• Selected for Merck's Inaugural Digital Sciences Studio Cohort on January 17, 2023.

• Financial Developments:

• Announced $1.5M investment from strategic and institutional investors in December 2022.

Products & Capabilities Highlighted:

• AD-Px™ Presentation:

• Featured at various conferences including AD/PD on March 9, 2024, and CTAD on October 24, 2023, for screening failure reduction efforts.

• Technological Advances:

• Integration of ISO standards to enhance data privacy within the Foresight platform.

• Foresight platform poised for clinical trial optimization using advanced AI forecasts.

• Media and Outreach:

• Featured in a podcast discussing AI’s role in Alzheimer's trials on May 31, 2024.

• Participation in global networks such as JLABS to drive platform development.

Conclusion

Perceiv AI remains at the forefront of precision medicine by continuously developing innovative solutions like its Foresight™ platform and AD-Px™ engine. The company demonstrates robust strategic partnerships and certifications that enhance its offerings in data privacy and clinical evaluation, while receiving recognition within the industry for its contributions to disease forecasting and clinical trial optimization. The dedication of key leaders with a wealth of experience further positions Perceiv AI towards transforming future medical diagnostics and treatments in age-related disorders.